Related Experiment Video

Updated: Mar 30, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.8K

Vancomycin Therapeutic Targets and Nephrotoxicity in Critically Ill Children With Cancer

Glaucia T F Seixas1, Orlei R Araujo, Dafne C B Silva

  • 1From the Pediatric Oncology Institute (IOP/GRAACC)/ Sao Paulo Federal University, Sao Paulo, Brazil.

Journal of Pediatric Hematology/Oncology
|November 13, 2015
PubMed

Insights

Current vancomycin doses are insufficient for critically ill pediatric cancer patients, failing to reach therapeutic targets. Higher trough levels increase nephrotoxicity risk, a predictor of death.

Area of Science:

  • Pharmacology
  • Pediatric Oncology
  • Critical Care Medicine

Background:

  • Vancomycin is crucial for treating serious Gram-positive infections in pediatric oncology patients.
  • Optimizing vancomycin dosing is essential to balance efficacy and toxicity in this vulnerable population.

Purpose of the Study:

  • To determine pharmacokinetic and pharmacodynamic parameters of vancomycin in critically ill pediatric oncology patients.
  • To identify risk factors for vancomycin-related nephrotoxicity and 28-day mortality.
  • To assess the adequacy of current dosing regimens in achieving therapeutic targets.

Main Methods:

  • Analysis of 256 vancomycin concentration measurements from 94 critically ill pediatric oncology patients.
  • Evaluation of pharmacokinetic parameters including clearance and volume of distribution.
  • Statistical analysis to identify risk factors for nephrotoxicity and death.

Main Results:

  • Mean vancomycin trough concentration was 15.6 ± 12.4 μg/mL; only 13.6% were within the 15-20 μg/mL therapeutic range.
  • Current doses (60 mg/kg/d) achieved the target AUC/MIC ≥ 400 in only 56% of cases (MIC=1).
  • Trough levels ≥ 20 μg/mL significantly increased nephrotoxicity risk (OR=17.83), which predicted 28-day mortality (OR=7.68).

Conclusions:

  • Current vancomycin dosing strategies are inadequate for critically ill pediatric cancer patients.
  • Higher vancomycin trough levels are associated with increased nephrotoxicity and mortality.
  • Therapeutic drug monitoring and dose adjustments are critical for optimizing vancomycin therapy in this population.

More Related Videos

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS08:24

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS

Published on: January 23, 2026

170
Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
487
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
580
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
462
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
297